Polycaprolactone spheres and theromosensitive pluronic F127 hydrogel for vocal fold augmentation: In vivo animal study for the treatment of unilateral vocal fold palsy

2013 ◽  
Vol 123 (7) ◽  
pp. 1694-1703 ◽  
Author(s):  
Seong Keun Kwon ◽  
Jae-Jun Song ◽  
Chang Gun Cho ◽  
Seok-Won Park ◽  
Soo Jung Choi ◽  
...  
PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e85512 ◽  
Author(s):  
Seong Keun Kwon ◽  
Hee-Bok Kim ◽  
Jae-Jun Song ◽  
Chang Gun Cho ◽  
Seok-Won Park ◽  
...  

2021 ◽  
Vol 9 (1) ◽  
pp. 108-115
Author(s):  
Soonmin Kwon ◽  
Hyunsu Choi ◽  
Changhee Park ◽  
Sangkee Choi ◽  
Eunha Kim ◽  
...  

A click chemistry-based PEG hydrogel was applied for vocal fold augmentation in vivo. In rabbit models, it stably fixed the paralyzed vocal fold and minimized the glottic gap.


2020 ◽  
Vol 21 (15) ◽  
pp. 1688-1698
Author(s):  
Germeen N.S. Girgis

Purpose: The work was performed to investigate the feasibility of preparing ocular inserts loaded with Poly-ε-Caprolactone (PCL) nanoparticles as a sustained ocular delivery system. Methods: First, Atorvastatin Calcium-Poly-ε-Caprolactone (ATC-PCL) nanoparticles were prepared and characterized. Then, the optimized nanoparticles were loaded within inserts formulated with Methylcellulose (MC) and Polyvinyl Alcohol (PVA) by a solvent casting technique and evaluated physically, for in-vitro drug release profile. Finally, an in-vivo study was performed on the selected formulation to prove non-irritability and sustained ocular anti-inflammatory efficacy compared with free drug-loaded ocuserts. Results: The results revealed (ATC-PCL) nanoparticles prepared with 0.5% pluronic F127 were optimized with 181.72±3.6 nm particle size, 0.12±0.02 (PDI) analysis, -27.4± 0.69 mV zeta potential and 62.41%±4.7% entrapment efficiency. Nanoparticles loaded ocuserts manifested compatibility between drug and formulation polymers. Moreover, formulations complied with average weight 0.055±0.002 to 0.143±0.023 mg, and accepted pH. ATC-PCL nanoparticles loaded inserts prepared by 5% MC showed more sustained, prolonged in-vitro release over 24h. In-vivo study emphasized non-irritability, ocular anti-inflammatory effectiveness represented by smaller lid closure scores, and statistically significant lowering in PMN count after 3h. Conclusion: These findings proposed a possibly simple, new and affordable price technique to prepare promising (ATC-PCL) nanoparticles loaded inserts to achieve sustained release with prolonged antiinflammatory efficacy.


PLoS ONE ◽  
2020 ◽  
Vol 15 (7) ◽  
pp. e0236348
Author(s):  
Naila Cannes do Nascimento ◽  
Andrea P. dos Santos ◽  
M. Preeti Sivasankar ◽  
Abigail Cox
Keyword(s):  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ryosuke Nakamura ◽  
Nao Hiwatashi ◽  
Renjie Bing ◽  
Carina P. Doyle ◽  
Ryan C. Branski

AbstractVocal fold (VF) fibrosis is a major cause of intractable voice-related disability and reduced quality of life. Excision of fibrotic regions is suboptimal and associated with scar recurrence and/or further iatrogenic damage. Non-surgical interventions are limited, putatively related to limited insight regarding biochemical events underlying fibrosis, and downstream, the lack of therapeutic targets. YAP/TAZ integrates diverse cell signaling events and interacts with signaling pathways related to fibrosis, including the TGF-β/SMAD pathway. We investigated the expression of YAP/TAZ following vocal fold injury in vivo as well as the effects of TGF-β1 on YAP/TAZ activity in human vocal fold fibroblasts, fibroblast-myofibroblast transition, and TGF-β/SMAD signaling. Iatrogenic injury increased nuclear localization of YAP and TAZ in fibrotic rat vocal folds. In vitro, TGF-β1 activated YAP and TAZ in human VF fibroblasts, and inhibition of YAP/TAZ reversed TGF-β1-stimulated fibroplastic gene upregulation. Additionally, TGF-β1 induced localization of YAP and TAZ in close proximity to SMAD2/3, and nuclear accumulation of SMAD2/3 was inhibited by a YAP/TAZ inhibitor. Collectively, YAP and TAZ were synergistically activated with the TGF-β/SMAD pathway, and likely essential for the fibroplastic phenotypic shift in VF fibroblasts. Based on these data, YAP/TAZ may evolve as an attractive therapeutic target for VF fibrosis.


2017 ◽  
Vol 31 (4) ◽  
pp. 513.e15-513.e23 ◽  
Author(s):  
Andrew M. Vahabzadeh-Hagh ◽  
Zhaoyan Zhang ◽  
Dinesh K. Chhetri

2015 ◽  
Vol 126 (1) ◽  
pp. E12-E17 ◽  
Author(s):  
Abigail Durkes ◽  
M. Preeti Sivasankar
Keyword(s):  

SLEEP ◽  
1996 ◽  
Vol 19 (6) ◽  
pp. 479-484 ◽  
Author(s):  
Tatsuya Sadaoka ◽  
Noriya Kakitsuba ◽  
Yuki Fujiwara ◽  
Ryuichi Kanai ◽  
Hiroaki Takahashi

Sign in / Sign up

Export Citation Format

Share Document